Preventice Solutions, a strategic partnership between eCardio Diagnostics and Preventice, will test the system. eCardio will manage and operate the system from its existing headquarters in Houston while the clinical research team and product development activities will operate from Preventice’s Rochester, Minn., location, according to a news release.
The system will evaluate ECGs and prioritize readings that show probable arrhythmias. The final interpretation will be provided by eCardio’s diagnostic testing facility. AliveCor, based in San Francisco, will use its algorithms to analyze ECGs from traditional cardiac monitors as well to compare the difference in analyses, according to the news release.
AliveCor and Preventice Solutions have already worked together on the AliveECG app, through which AliveCor users receive an analysis service offering expert review of ECGs. Users send ECG readings to remote cardiac technicians for interpretation, paying either $2 to get a report back within 24 hours or $5 to get their report back within 30 minutes, according to the news release.
